Arkolith/Insider Trading/REPH/Form 4

Enloe J David JR

Chief Executive Officer, DirectorRecro Pharma, Inc. (REPH) · full profile →Form 4 · filed Jan 19, 2022
Net Buying
Open-Market Buys
$1K
Open-Market Sells
$0
Net Open-Market Flow
$1K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 18, 2022Buy(P)602$1.68$1K155K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000899243-22-002423) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML